0
Post your comment
Last updated: 23 April 2012
The public health arm of the United Nations is World Health Organisation (WHO).
WHO provides guidelines in the area of quality assurance of pharmaceutical products. These guidelines are established and maintained through a consultative procedure and adopted by the WHO Expert Committee on Specifications for Pharmaceutical Preparations. They are submitted to the WHO’s governing bodies for endorsement and subsequent implementation by Member States.
WHO strives to:
The guidance documents include recommendations in the area of good manufacturing practices and inspection, product assessment and registration, distribution, quality control, laboratory services, and international trade in pharmaceuticals.
I. General guidelines
WHO has adopted the following guidelines regarding generics:
Multisource (generic) pharmaceutical products: guidelines on registration requirements to establish interchangeability, Annex 7, WHO Technical Report Series, No. 937.
Effective date: 2006
www.apps.who.int/prequal/info_general/documents/TRS937/WHO_TRS_937__annex7_eng.pdf
Proposal to waive in vivo bioequivalence requirements for the WHO model list of essential medicines immediate release, solid oral dosage forms, Annex 8, WHO Technical Report Series, No. 937.
Effective date: 2006
www.apps.who.int/prequal/info_general/documents/TRS937/WHO_TRS_937__annex8_eng.pdf
Additional guidance for organizations performing in vivo bioequivalence studies, Annex 9, WHO Technical Report Series, No. 937.
Effective date: 2006
www.apps.who.int/prequal/info_general/documents/TRS937/WHO_TRS_937_eng.pdf#page=451
Guideline on submission of documentation for a multisource (generic) finished pharmaceutical product (FPP): preparation of product dossiers (PDS) in common technical document (CTD) format
Effective date: 2010
www.apps.who.int/prequal/info_general/documents/generic_guide/GenericGuideline_PDS_CTD-Format.pdf
Guideline on submission of documentation for a multisource (generic) finished pharmaceutical product (FPP): quality part
Effective date: 2010
www.apps.who.int/prequal/info_general/documents/generic_guide/GenericGuideline_Quality.pdf
II. WHO prequalification programme
In addition to enabling wider access to medicines, the WHO prequalification programme project has contributed to improving standards of generics producers and helped enhance countries’ capacity to produce quality medicines.
WHO has adopted the following guideline regarding generics that qualify for the prequalification programme:
Guideline on submission of documentation for prequalification of multi-source (generic) finished pharmaceutical products (FPPs) used in the treatment of HIV/AIDS, Malaria and Tuberculosis
Effective date: 12 May 2005
www.apps.who.int/prequal/info_applicants/Guidelines/GuideGenericSubmitDocFPPs_08_2005_WoAnnexes.pdf
Related article
WHO prequalification programme for medicines
Source: WHO
Strategic plans of ANVISA and COFEPRIS to advance health regulation
Panama enacts new bill to guarantees the supply of medicines
Follow-on biological/biosimilar approvals in Latin America by therapeutic class
Follow-on biological/biosimilar approvals landscape in Latin America
The best selling biotechnology drugs of 2008: the next biosimilars targets
Global biosimilars guideline development – EGA’s perspective
New decree for the prescription and commercialization of medicines in Argentina
FDA issues draft guidance on biosimilars and interchangeable biosimilars labelling
WHO’s revised guideline to safe and effective biosimilar products
New FDA guidance on statistical approaches to establishing bioequivalence
Sign up today for the weekly briefing on the latest developments in generic and biosimilar medicines!
Post your comment